Kristen Ducote
Family Medicine · Baton Rouge, LANPI 1154680643
Payments from drug & device makers
Across 163 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$900
- Alkermes, Inc.$320
- Lundbeck LLC$196
- GSK$149
- Amarin Pharma, Inc.$148
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$145
- plus $901 from 23 others
What the payments were for
- Food & beverage$2,757100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $900 |
| Alkermes, Inc. | 16 | $320 |
| Lundbeck LLC | 10 | $196 |
| GSK | 9 | $149 |
| Amarin Pharma, Inc. | 10 | $148 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $145 |
| Amgen | 7 | $114 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Lilly USA, LLC | 5 | $88 |
| Novo Nordisk | 4 | $70 |
| Gilead | 4 | $69 |
| Indivior Inc. | 3 | $61 |
| Braeburn Inc. | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 3 | $42 |
| UCB, Inc. | 2 | $32 |
| Pfizer | 2 | $28 |
| Almatica Pharma LLC | 1 | $26 |
| Tolmar, Inc. | 1 | $21 |
| Acerus Pharmaceuticals Corporation | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$2,757 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $50,975 |
| RexultiBrexpiprazole | 22 | $39,378 |
| OzempicSemaglutide | 34 | $37,693 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 134 | $34,182 |
| VraylarCariprazine Hcl | 13 | $17,867 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 21 | $14,477 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,105 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $9,900 |
| TradjentaLinagliptin | 15 | $9,486 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 121 | $4,241 |
| Lisdexamfetamine Dimesylate | 18 | $4,190 |
| Buprenorphine | 22 | $3,941 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 11 | $2,216 |
| Testosterone Cypionate | 51 | $2,018 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $69 | $50,97511 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $92 | $39,37822 claims |
| Novo NordiskOzempic | $70 | $37,69334 claims |
| AbbVieVraylar, Synthroid | $900 | $18,49827 claims |
| Indivior Inc.Suboxone | $61 | $14,47721 claims |
| GSKTrelegy Ellipta | $149 | $10,10516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Baton Rouge
- Christine SmithBaton Rouge$185K
- Kevin DibenedettoBaton Rouge$80K
- Stan MaysBaton Rouge$15K
- Myles JaynesBaton Rouge$15K
- Yushen LeeBaton Rouge$14K
- Gerald BarberBaton Rouge$14K
- Vincent NguyenBaton Rouge$13K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.